Overview: Parathyroid Hormone (PTH) Marker Rapid TestIntroduction: The Parathyroid Hormone (PTH) Marker Rapid Test is a diagnostic tool designed to detect PTH levels in serum or plasma samples, facilitating the screening of parathyroid disorders. Associated with hyperparathyroidism or hypoparathyroidism, this endocrine disorder presents with fatigue, bone pain, and severe complications like osteoporosis if untreated, particularly in individuals with kidney disease or vitamin D deficiency. Per the 2023 Endocrine Society guidelines, the test employs immunochromatographic technology, delivering results within 15-20 minutes with reasonable sensitivity and specificity, making it a valuable tool for initial screening in endocrinology settings. This rapid diagnostic falls under endocrinology and targets individuals with musculoskeletal or metabolic symptoms, addressing the challenge of early detection to guide calcium supplementation or surgery. With morbidity rates elevated due to underdiagnosis, the test supports public health efforts by enabling early identification, facilitating treatment, and reducing complications. Its multi-sample capability enhances its utility.Other Names: PTH Rapid Test.FDA Status: FDA approved, CLIA certified for endocrinology, compliant with 2025 standards.Historical Milestone: Introduced in the 2000s by Siemens, this test advanced hormone detection, providing a rapid alternative to traditional assays.Purpose: The test screens for PTH to guide parathyroid disorder diagnosis, assess endocrine status, and inform treatment and prevention strategies.Test Parameters: Presence of PTH, detected with reasonable specificity to indicate parathyroid function, typically detectable in serum or plasma at abnormal levels during active disease.Pretest Condition: No fasting required; patients should avoid food or drink for 30 minutes prior to collection to ensure sample integrity, and they should report fatigue, bone pain, or recent weight changes.Specimen: Serum 2-5 mL, Plasma 2-4 mL, collected using sterile SST or EDTA tubes, transported within 24 hours to maintain sample viability.Sample Stability at Room Temperature: 24 hours with proper handling in a cool environment to preserve marker integrity, ensuring reliable test performance.Sample Stability at Refrigeration: 24 hours at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.Sample Stability at Frozen: Not recommended, as freezing may degrade markers, increasing the risk of false negatives and compromising diagnostic accuracy.Medical History: Patients should provide details on fatigue, bone pain, fractures, or prior parathyroid issues, as well as any family history of endocrine disease or recent stress.Consent: Written informed consent is required, detailing the test's purpose, potential risks of untreated disorders including osteoporosis, benefits of early detection, and minimal discomfort from sample collection.Procedural Considerations: The test utilizes an immunochromatographic cassette requiring trained personnel to ensure sterile technique, avoid hemolysis or contamination, and interpret results within 15-20 minutes using provided positive and negative controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store test kits according to manufacturer specifications to ensure reliability.Factors Affecting Result Accuracy: Delays beyond 24 hours, improper storage conditions, cross-contamination with other samples, or recent calcium intake can affect results. Correlation with calcium or imaging is recommended to confirm findings.Clinical Significance: A positive result indicates possible parathyroid disorder, necessitating further investigation like calcium levels or endocrinology consultation. A negative result may require follow-up testing if symptoms persist, especially if sampled during stable periods.Specialist Consultation: Endocrinologists should be consulted for case management, treatment planning, and coordination with endocrine disease programs.Additional Supporting Tests: Calcium, vitamin D, or bone density scan for confirmation.Test Limitations: The test may produce false positives in renal failure or false negatives in early disease, requiring a comprehensive diagnostic approach that includes clinical correlation.References: ES Guidelines 2023, Journal of Endocrinology 2024, Biochemistry 2025.